PLATFORM
Partner with us
How we work
WORKFLOW
Safety-first, biomarker-led drug discovery.
Identify
Integrate cancer dependency, tumor, normal-tissue and biomarker evidence.
Prioritize
Select targets with therapeutic window, patient-selection logic and modality fit.
Validate
Confirm biology in disease-relevant models, patient-derived systems and normal comparators.
Partner
Package targets or target + molecule assets for early licensing and collaboration
ONCOTARGET PLATFORM
Our proprietary platform combines in silico assessment with biological validation enabling identification of novel and underexplored cancer-specific and safe targets across 135+ different cancer types and multiple modalities.
Our current pipeline caters to hematological malignancies, ovarian cancer, and glioblastoma, with the aim of early out-licensing or sales. Target and program cataloque will be expanded based on market input.
DISCOVERY INPUTS
- Bioinformatics and AI – Human-guided in-silico analysis
- Patient-derived cell/tissue validation – Translational confidence
- Normal healthy vs cancer tissue – Safety-first filter
- Functional genomics – Dependency evidence
- Multi-omics – Cancer biology datasets
PLATFORM OUTPUTS
- Novel targets – Cancer-specific biology across 135+ cancer types.
- Partner-ready asset – Prepared for collaboration or licensing
- Validation package – Patient-derived and normal comparators
- Biomarker strategy – Selecting the patients most likely to benefit
- Modality independent – Targets for a wide range of therapies